mangafodipir trisodium
Trade name: teslascan
Approved
Nov 26, 1997
Mangafodipir (sold under the brand name Teslascan as mangafodipir trisodium) is a contrast agent delivered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver. Mangafodipir is a manganese (Mn2+) chelate with the ligand fodipir (dipyridoxyl diphosphate or DPDP). Mangafodipir trisodium is metabolised (dephosphorylated) and partially transmetallated (manganese exchanged for zinc) after intravenous administration. Manganese that is released from mangafodipir is taken up by hepatocytes thereby increasing the SI of normal liver tissue. This may result in an improvement of the detection of liver metastases, which usually have no hepatocytes. The metabolites of fodipir are renally excreted, whilst the biliary route mainly excretes manganese. Mangafodipir was withdrawn from the US market in 2003 and the European market in 2012. — NCATS
Clinical trial activity
8 trials · 7 clinical orgs · 1 marketing orgs
Earliest trial started Jun 1, 2008 (NCT00671996)
Timeline
1990s
- Nov 26, 1997
IC Targets — Earliest FDA Approval
- Nov 26, 1997
IC Targets — NDA Secondary Org
- Nov 26, 1997
IC Targets — NDA Organization
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedNov 26, 1997
Chemistry & pharmacology
SMILES
[H+].[H+].[H+].[H+].[Mn++].CC1=NC=C(COP([O-])([O-])=O)C(CN(CCN(CC([O-])=O)CC2=C(COP([O-])([O-])=O)C=NC(C)=C2O)CC([O-])=O)=C1O- Mol. weight
- 691.3776 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaMangafodipir ↗
- NCATSN02W67RKJS ↗
- ChEMBLCHEMBL2096651 ↗
- ChEMBLCHEMBL1201301 ↗
Also known as
- ca4mn(dpdp)5
- calmangafodipir
- calmangafodipir
- calmangafodipir
- dpdp
- mangafodipir
- mangafodipir
- mangafodipir
- mangafodipir
- mangafodipir
- mangafodipir
- mangafodipir
- mangafodipir trisodium
- mangafodipir trisodium
- mangafodipir trisodium
- mangafodipir trisodium
- mangafodipir trisodium
- mangafodipir trisodium
- mangafodipir trisodium
- mangafodipir trisodium, anhydrous
- manganese dipyridoxyl diphosphate
- manganese-dpdp
- mn-dpdp
- n,n'-bis(pyridoxal-5-phosphate)ethylenediamine-n,n'-diacetic acid
- nycomed brand of mangafodipir trisodium
- teslascan
- teslascan
- teslascan
- teslascan
- win-59010
- win-59010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06731738 | Phase 2 | Nov 22, 2024 | IC Targets |
| NCT03430999 | Phase 1 | Nov 7, 2017 | PledPharma AB |
| NCT03177395 | Phase 1 | Jun 8, 2017 | NHS Lothian, PledPharma AB, University of Edinburgh |
| NCT02531880 | Phase 1 | Aug 6, 2015 | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT01326715 | Phase 1 | Mar 4, 2011 | National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) |
| NCT00966563 | Phase 2 | Dec 1, 2009 | PledPharma AB |
| NCT00671996 | Phase 2 | Jun 1, 2008 | PledPharma AB |
| NCT00727922 | Phase 2 | Jun 1, 2008 | University of Paris |
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PledPharma AB | For profit | 4 | 4 | 2 | 2008 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 2 | 2 | 1 | 2011 |
| IC Targets | For profit | 1 | 1 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
| NHS Lothian | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Edinburgh | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2008 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| IC Targets | For profit | NDA2 | Nov 26, 1997 |
| IC Targets | For profit | NDA | Nov 26, 1997 |